SpecificationsOrganism/cell line/tissueHomo sapiens/colon and rectumSexAll maleSequencer or array typeThe Illumina human miRNA Sentrix Universal Array Matrix (SAM) V1 arraysData formatRaw and analyzedExperimental factorsTumor, normal, metastasis and background tissuesExperimental featuresUICC stage IVConsentInformed consent and ethical approval obtained from patients and ethical committee, respectivelySample source locationUMM Mannheim, Germany

1. Direct link to deposited data {#s0005}
================================

<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE54088>.

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Experimental design {#s0015}
------------------------

Tissue samples from colorectal cancer patients comprising the primary tumor, adjacent normal tissue, resected metastasis and the normal background tissue in which the metastasis occurred were obtained from and used for miRNA profiling ([Fig. 1](#f0005){ref-type="fig"}).

2.2. Materials and methods {#s0020}
--------------------------

### 2.2.1. Patient material {#s0025}

Tumor, metastasis, and corresponding normal and background tissue samples of patients with colorectal cancer were stored and obtained from the tumor bank of the Mannheim Medical Faculty, University of Heidelberg, Germany. The biobank was approved by the Ethical Committee of the Medical Faculty, University Hospital Mannheim, and informed consent was obtained from patients or their spouses when the former were deceased. Tissue sections and specimen were prepared by pathologists prior to snap freezing and subsequent storage in liquid nitrogen prior to sectioning. Biobanking and handling of the tissues followed the BRISQ guidelines [@bb0005]. 20--30, 20 μm sections/sample (depending on tissue size) were made in a cryotome and used for RNA extraction. All samples had at least 80% tumor cell content.

### 2.2.2. Patient characteristics {#s0030}

Nine patients in total were profiled, four with primary colonic tumors and six with rectal tumors. One patient had a primary tumor in both colon and rectum and accounts for the extrarectal tumor sample. All patients had stage IV disease with distant metastasis to either the liver or lung. 8 of these patients had additional mRNA profiling data and were included in the subsequent analysis as published in [@bb0010]. An overview of the patients is given in [Table 1](#t0005){ref-type="table"}.

### 2.2.3. RNA isolation {#s0035}

Total RNA, including small RNAs, was isolated using the miRNeasy mini kit (Qiagen, Hilden, Germany) according to the manufacturer\'s instructions. Briefly, the thin cryosections were homogenized by vortexing in QIAzol lysis reagent followed by chloroform separation and column purification. RNA concentration was measured using the Nanodrop spectrophotometer, and RNA quality was evaluated on StdSens chips using lab-on-chip automated electrophoresis (BioRad, Germany). Only samples with an RNA quality index (RQI) greater than or equal to 7 were used for further downstream processing.

### 2.2.4. In vitro transcription, amplification, labeling and hybridization {#s0040}

In general, the Illumina human miRNA Sentrix Universal Array Matrix (SAM) protocol was used. Briefly, 200 ng total RNA was polyadenylated with a PAP enzyme (Poly-A Polymerase) and then reverse transcribed using biotinylated oligo-dT primers. The cDNA templates were then hybridized with miRNA-specific oligos (MSOs) and unbound oligos were washed away. After second-strand cDNA synthesis and PCR amplification with fluorescently labeled primers, the labeled products were hybridized and signals detected with the Illumina BeadScan reader. For quality assurance purposes, control samples were added and evaluated at the polyadenylation, first strand synthesis, hybridization of miRNA-specific oligos, second strand synthesis, fluorophore incorporation and array hybridization steps.

### 2.2.5. Data normalization {#s0045}

Quantile normalization was applied using all array data from the experiment. Resulting data were log2 transformed.

### 2.2.6. Statistical analysis {#s0050}

Pairwise comparisons were performed to test differential miRNA expression between paired samples. First, normal and tumor tissues were compared. We selected the colon samples from the patient where we had colon and rectum samples to get a design that was nearly balanced with respect to tumor site. Additional tests were performed for colon and rectum samples separately. Paired tests for differences between pairs of metastasis and corresponding normal tissue in the liver and lung were computed. Finally, we compared pairs of tumor samples and corresponding metastases. This was done as well for distant-site normal colorectal tissue samples corresponding to the primary tumor of the respective patients. We then identified those miRNAs with significant differences in the comparison of metastasis taking the differences between metastasis and the surrounding normal tissue into account. A multiplicity adjusted significance level of 5% was used in all comparisons. Venn diagrams were used to display comparatively the different sets of significant miRNAs. The statistical analyses were performed using the approach described by Smyth [@bb0015]. Adjustment for multiple testing was done by controlling the false discovery rate [@bb0020], [@bb0025]. All statistical analyses were performed within the R statistical software environment (R version 2.15.3) using the R/Bioconductor packages beadarray [@bb0030], version 2.6.0, and limma, version 3.14.4. MicroRNAs with an estimated fold change of ≥ 1.5 and adjusted p-value ≤ 0.1 were considered for further evaluation.

3. Discussion {#s0055}
=============

We have described here a very unique data set of patients with advanced colorectal cancer in which primary tumor and metastasis were evaluated alongside their corresponding normal samples. This data set is further supported by additional clinical data that could be exploited in deciphering clinical associations; however, the small sample size limits this applicability. This data set has been used as a source of hypothesis generation to discern and investigate microRNAs that impact metastasis in colorectal cancer. The outcome of such analyses has led to the generation of our recent manuscript [@bb0010].
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![Schematic representation of experimental flow. RNA was extracted from primary tumor, normal mucosa, and metastasis and background tissue of colorectal cancer patients. Total RNA was subsequently processed for miRNA and mRNA profiling using microarray platforms. The data presented in this manuscript is only for the miRNA data, in which 9 patients were profiled, but one was dropped for subsequent comparative analysis with the mRNA data.](gr1){#f0005}
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Bio-sketch of profiled patients.

  --------------------------------------------------------------------------------------------------------------------------------------------------
  Sr.\   Anonymized IDs   Age[⁎](#tf0005){ref-type="table-fn"}   Gender   Histology        Tumor\          Grade   TNM\             UICC\
  No                                                                                       presentation            classification   classification
  ------ ---------------- -------------------------------------- -------- ---------------- --------------- ------- ---------------- ----------------
  1      P2               59                                     Male     Adenocarcinoma   Rectum          G 2     pT3, pN1, pM1    Stage IV

  2      P4               76                                     Male     Adenocarcinoma   Sigmoid colon   G 2     pT3, pN1, pM1    Stage IV

  3      P6               65                                     Male     Adenocarcinoma   Sigmoid colon   G 2     pT3, pN0, pM1    Stage IV

  4      P7               65                                     Male     Adenocarcinoma   Rectum          G 2     pT3, pN0, pM1    Stage IV

  5      P8               66                                     Male     Adenocarcinoma   Colon           G 2     pT4, pN1, pM1    Stage IV

  6      P8               66                                     Male     Adenocarcinoma   Rectum          G 2     PT2, pN0, pM1    Stage IV

  7      P9               71                                     Male     Adenocarcinoma   Sigmoid colon   G 3     pT4, pN2, pM1    Stage IV

  8      P10              49                                     Male     Adenocarcinoma   Recto-sigmoid   G 2     pT3, pN1, pM1    Stage IV

  9      P11              65                                     Male     Adenocarcinoma   Recto-sigmoid   G 2     pT3, pN2, pM1    Stage IV

  10     P12              50                                     Male     Adenocarcinoma   Rectum          G 3     pT2, pN2, pM1    Stage IV
  --------------------------------------------------------------------------------------------------------------------------------------------------

Age at surgery in years.
